Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYRAMZA vs PORTRAZZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.
PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Gastric or gastroesophageal junction adenocarcinoma, as monotherapy or with paclitaxel,Non-small cell lung cancer (NSCLC), in combination with docetaxel,Metastatic colorectal cancer, in combination with FOLFIRI,Hepatocellular carcinoma (HCC), as monotherapy,Off-label: Advanced urothelial carcinoma, endometrial cancer
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.
8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
Terminal elimination half-life is approximately 14 days (range 11–17 days) at steady state, supporting a dosing interval of every 2 weeks.
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Ramucirumab is a monoclonal antibody; metabolism is via catabolism into small peptides and amino acids (nonspecific proteolytic degradation). No major metabolic enzymes involved.
Metabolism of necitumumab has not been fully characterized. As a monoclonal antibody, it is expected to be degraded into small peptides and amino acids via general protein catabolic pathways.
Ramucirumab is eliminated primarily via proteolytic catabolism; no renal or biliary excretion occurs. Clearance is 0.014 L/h (0.022 L/h with high VEGF), with a mean terminal half-life of 14 days (range 11–17 days) at steady state.
Necitumumab is an Ig G1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Approximately 95% bound to serum proteins, primarily albumin and immunoglobulins.
Necitumumab is a monoclonal antibody; target-mediated binding to EGFR occurs, but nonspecific plasma protein binding is negligible. No specific protein binding percentage is reported.
Volume of distribution at steady state is approximately 5.0–6.0 L, corresponding to 0.07–0.09 L/kg (assuming 70 kg body weight), indicating limited extravascular distribution primarily within plasma volume.
Volume of distribution at steady state is approximately 5.8 L (range 4.7–7.1 L), suggesting distribution primarily in the vascular space and minimal extravascular distribution.
Bioavailability is 100% as ramucirumab is administered only by intravenous infusion; no oral or other form is available.
Intravenous: 100% (not applicable to other routes).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not studied in severe renal impairment or dialysis.
No dose adjustment is recommended for patients with mild to moderate renal impairment. There is no data for severe renal impairment (Cr CL <30 m L/min) or end-stage renal disease.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). For moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, no dosing information available; use with caution.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended for mild hepatic impairment (Child-Pugh A). Use caution in moderate to severe hepatic impairment due to lack of data.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
No dose adjustment required based on age. Monitor for increased risk of adverse events such as hypertension, hemorrhage, and gastrointestinal perforations.
No specific dose adjustment is recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger patients.
Hemorrhage: Severe or fatal hemorrhage, including gastrointestinal hemorrhage, hemoptysis, and intracranial hemorrhage, has occurred. Do not administer in patients with severe bleeding.
No black box warnings.
Hemorrhage risk: Serious and sometimes fatal hemorrhagic events; permanently discontinue if severe bleeding occurs.,Arterial thromboembolic events: Including myocardial infarction and stroke; discontinue if occurs.,Gastrointestinal perforation: Fatal cases reported; discontinue if occurs.,Impaired wound healing: Interrupt therapy 28 days prior to elective surgery; do not resume until wound fully healed.,Hypertension: Monitor blood pressure; treat with antihypertensives; temporarily withhold if severe hypertension occurs.,Proteinuria: Monitor urine protein; withhold for >2 g/24h; discontinue if nephrotic syndrome develops.,Hypersensitivity/infusion reactions: Permanently discontinue if severe reaction occurs.,Thyroid dysfunction: Monitor thyroid function during treatment.
Cardiopulmonary arrest and/or sudden death occurred in 3% of patients receiving necitumumab in combination with gemcitabine and cisplatin; monitor electrolytes and consider withholding for severe electrolyte abnormalities.,Arterial thromboembolic events (ATEs) occurred in 5% of patients; permanently discontinue for serious ATEs.,Venous thromboembolic events (VTEs) including pulmonary embolism occurred; permanently discontinue for life-threatening VTEs.,Hemolytic-uremic syndrome (HUS) reported; discontinue if HUS is suspected.,Dermatologic toxicities including rash, dry skin, and pruritus; monitor and manage accordingly.,Infusion-related reactions; interrupt or discontinue for severe reactions.,Hypomagnesemia occurred in 83% of patients; monitor magnesium, calcium, and potassium prior to each dose.,Embryofetal toxicity: can cause fetal harm; advise females of reproductive potential of effective contraception.
Severe hemorrhage (active bleeding),Hypersensitivity to ramucirumab or any excipients
No known contraindications from the manufacturer.
No specific food interactions are documented. Avoid grapefruit juice if taking concomitant drugs metabolized by CYP3A4 (e.g., simvastatin) due to potential interaction, but no direct interaction with ramucirumab.
No specific food interactions have been identified with necitumumab. However, maintain adequate hydration and nutrition. Grapefruit and other CYP3A4 inhibitors are not expected to interact since necitumumab is a monoclonal antibody cleared via proteolysis.
Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal reproduction studies, intravenous administration of ramucirumab to pregnant rabbits during organogenesis resulted in embryofetal mortality and reduced fetal weight at exposures less than the recommended human dose. There are no adequate and well-controlled studies in pregnant women. Cyramza is contraindicated in pregnancy. First trimester: High risk of teratogenicity; VEGF inhibition interferes with embryonic vascular development. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and potential for fetal renal impairment due to anti-angiogenic effects. Avoid use during pregnancy.
Portrazza (necitumumab) is an Ig G1 monoclonal antibody. Ig G molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to therapeutic concentrations. There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (EGFR inhibition), there is a risk of fetal harm, including developmental abnormalities and fetal loss. Women of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose.
No human data available on the presence of ramucirumab in human milk, effects on the breastfed infant, or effects on milk production. Ramucirumab is a large protein molecule (Ig G1 monoclonal antibody) and is likely to be present in breast milk at low levels, especially in early postpartum period. However, because of the potential for serious adverse reactions in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 months after the last dose. M/P ratio: Not determined.
It is not known whether necitumumab is excreted in human milk. Human Ig G is known to be present in milk, but the amount is generally low. Due to the potential for serious adverse reactions in nursing infants, advise women not to breast-feed during treatment and for at least 3 months after the last dose. M/P ratio is unknown.
Cyramza is contraindicated in pregnancy; no dosing adjustments are recommended as use should be avoided. If used inadvertently, no specific pharmacokinetic data in pregnancy are available; however, physiological changes (e.g., increased plasma volume, altered renal function) may affect drug clearance, but no dose adjustment guidelines exist. The risk of fetal harm outweighs any potential benefit, and treatment should be discontinued immediately if pregnancy occurs.
No specific dosing adjustments for pregnancy are established. However, physiological changes during pregnancy (e.g., increased plasma volume, altered renal clearance) may affect pharmacokinetics. Currently, no dose modification is recommended due to lack of data; however, caution is advised, and treatment should only be used if the potential benefit justifies the potential risk to the fetus.
CYRAMZA (ramucirumab) is a VEGFR-2 antagonist; premedicate with antihistamines and acetaminophen before infusion to reduce infusion-related reactions. Monitor blood pressure closely as hypertension is common; hold for severe hypertension. Avoid use in patients with significant bleeding risk or recent thromboembolic events. Do not administer with platinum-based chemotherapy in NSCLC patients with EGFR or ALK mutations unless progression on targeted therapy.
PORTRAZZA (necitumumab) is a human Ig G1 monoclonal antibody targeting EGFR. Prior to initiation, confirm EGFR expression in squamous non-small cell lung cancer. Premedicate with H1 antagonists to reduce infusion-related reactions. Monitor for hypomagnesemia, which can occur weeks after treatment; replete as needed. Avoid use in patients with a history of severe infusion reactions to other EGFR inhibitors.
You may experience high blood pressure; monitor regularly and report symptoms like severe headache or vision changes.,This drug can increase bleeding risk; inform your doctor if you have any unusual bruising or bleeding.,Infusion reactions may occur; you will receive premedication to reduce this risk.,Report any new or worsening shortness of breath, chest pain, or leg swelling as these could be signs of blood clots or heart problems.,Wound healing may be impaired; avoid elective surgery during treatment and inform all healthcare providers you are on this medication.,Effective contraception is required during treatment and for at least 3 months after final dose.
Inform your doctor if you experience severe skin rash, diarrhea, or infusion reactions during treatment.,Report any signs of low magnesium such as muscle cramps, numbness, or irregular heartbeat.,Avoid sun exposure and use broad-spectrum sunscreen SPF 50+; this drug increases photosensitivity.,Do not receive live vaccines while on PORTRAZZA.,Use effective contraception during treatment and for 3 months after the last dose if you are of childbearing potential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYRAMZA vs PORTRAZZA, answered by our medical review team.
CYRAMZA is a Antineoplastic Monoclonal Antibody that works by Ramucirumab is a human Ig G1 monoclonal antibody that binds to vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks the interaction between VEGFR-2 and its ligands, VEGF-A, VEGF-C, and VEGF-D, thereby inhibiting receptor activation and subsequent angiogenesis.. PORTRAZZA is a Antineoplastic Monoclonal Antibody that works by PORTRAZZA (necitumumab) is a recombinant human Ig G1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYRAMZA and PORTRAZZA depend on the specific clinical indication. These are both Antineoplastic Monoclonal Antibody agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYRAMZA is: 8 mg/kg intravenously every 2 weeks or 10 mg/kg intravenously every 2 weeks if used in combination with paclitaxel or FOLFIRI.. The standard adult dose of PORTRAZZA is: PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYRAMZA and PORTRAZZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYRAMZA is classified as Category C. Cyramza (ramucirumab) is a VEGF receptor antagonist. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to pregnant women. In animal rep. PORTRAZZA is classified as Category C. Portrazza (necitumumab) is an IgG1 monoclonal antibody. IgG molecules are actively transported across the placenta during the third trimester, potentially exposing the fetus to the. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.